Hyperkalemia associated with rapid infusion of conventional and lipid complex formulations of amphotericin B.
A child developed hyperkalemia and cardiac arrest with infusion of an amphotericin B lipid complex 5.0 mg/kg over 1 hour. Another child, with chronic renal failure, developed hyperkalemia after infusion of conventional amphotericin B deoxycholate 1.0 mg/kg over 2 hours. Rapid infusion of the agent causes hyperkalemia in dogs and humans that is exacerbated in the setting of renal failure. A lipid formulation of amphotericin B is commercially available, and no reports of hyperkalemia are associated with its administration.
Barcia
J P
JP
Legacy Emanuel Children's Hospital, and Northwest Pediatric Kidney Specialists, Portland, Oregon 97227, USA.
D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D002177:Candidiasis / Q000188:drug therapy; D002675:Child, Preschool; D004338:Drug Combinations; D005260:Female; D006801:Humans; D006947:Hyperkalemia / Q000139:chemically induced*; D007262:Infusions, Intravenous; D008297:Male; D010713:Phosphatidylcholines / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use
D000935:Antifungal Agents; D004338:Drug Combinations; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B